Research progress of dihydromyricetin in the treatment of diabetes mellitus
Diabetic Mellitus (DM), a chronic metabolic disorder disease characterized by hyperglycemia, is mainly caused by the absolute or relative deficiency of insulin secretion or decreased insulin sensitivity in target tissue cells. Dihydromyricetin (DMY) is a flavonoid compound of dihydroflavonol that wi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1216907/full |
| _version_ | 1797693179575664640 |
|---|---|
| author | Ziyuan Wang Zhuoran Cao Zhiying Yue Zhengfeng Yang |
| author_facet | Ziyuan Wang Zhuoran Cao Zhiying Yue Zhengfeng Yang |
| author_sort | Ziyuan Wang |
| collection | DOAJ |
| description | Diabetic Mellitus (DM), a chronic metabolic disorder disease characterized by hyperglycemia, is mainly caused by the absolute or relative deficiency of insulin secretion or decreased insulin sensitivity in target tissue cells. Dihydromyricetin (DMY) is a flavonoid compound of dihydroflavonol that widely exists in Ampelopsis grossedentata. This review aims to summarize the research progress of DMY in the treatment of DM. A detailed summary of related signaling induced by DMY are discussed. Increasing evidence implicates that DMY display hypoglycemic effects in DM via improving glucose and lipid metabolism, attenuating inflammatory responses, and reducing oxidative stress, with the signal transduction pathways underlying the regulation of AMPK or mTOR/autophagy, and relevant downstream cascades, including PGC-1α/SIRT3, MEK/ERK, and PI3K/Akt signal pathways. Hence, the mechanisms underlying the therapeutic implications of DMY in DM are still obscure. In this review, following with a brief introduction of the absorption, metabolism, distribution, and excretion characteristics of DMY, we summarized the current pharmacological developments of DMY as well as possible molecular mechanisms in the treatment of DM, aiming to push the understanding about the protective role of DMY as well as its preclinical assessment of novel application. |
| first_indexed | 2024-03-12T02:39:49Z |
| format | Article |
| id | doaj.art-f79646da3b5245c3b53cf13ffd89201f |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-12T02:39:49Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-f79646da3b5245c3b53cf13ffd89201f2023-09-04T09:16:37ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-09-011410.3389/fendo.2023.12169071216907Research progress of dihydromyricetin in the treatment of diabetes mellitusZiyuan WangZhuoran CaoZhiying YueZhengfeng YangDiabetic Mellitus (DM), a chronic metabolic disorder disease characterized by hyperglycemia, is mainly caused by the absolute or relative deficiency of insulin secretion or decreased insulin sensitivity in target tissue cells. Dihydromyricetin (DMY) is a flavonoid compound of dihydroflavonol that widely exists in Ampelopsis grossedentata. This review aims to summarize the research progress of DMY in the treatment of DM. A detailed summary of related signaling induced by DMY are discussed. Increasing evidence implicates that DMY display hypoglycemic effects in DM via improving glucose and lipid metabolism, attenuating inflammatory responses, and reducing oxidative stress, with the signal transduction pathways underlying the regulation of AMPK or mTOR/autophagy, and relevant downstream cascades, including PGC-1α/SIRT3, MEK/ERK, and PI3K/Akt signal pathways. Hence, the mechanisms underlying the therapeutic implications of DMY in DM are still obscure. In this review, following with a brief introduction of the absorption, metabolism, distribution, and excretion characteristics of DMY, we summarized the current pharmacological developments of DMY as well as possible molecular mechanisms in the treatment of DM, aiming to push the understanding about the protective role of DMY as well as its preclinical assessment of novel application.https://www.frontiersin.org/articles/10.3389/fendo.2023.1216907/fulldihydromyricetindiabetesdiabetes complicationsAMPKresearch progress |
| spellingShingle | Ziyuan Wang Zhuoran Cao Zhiying Yue Zhengfeng Yang Research progress of dihydromyricetin in the treatment of diabetes mellitus Frontiers in Endocrinology dihydromyricetin diabetes diabetes complications AMPK research progress |
| title | Research progress of dihydromyricetin in the treatment of diabetes mellitus |
| title_full | Research progress of dihydromyricetin in the treatment of diabetes mellitus |
| title_fullStr | Research progress of dihydromyricetin in the treatment of diabetes mellitus |
| title_full_unstemmed | Research progress of dihydromyricetin in the treatment of diabetes mellitus |
| title_short | Research progress of dihydromyricetin in the treatment of diabetes mellitus |
| title_sort | research progress of dihydromyricetin in the treatment of diabetes mellitus |
| topic | dihydromyricetin diabetes diabetes complications AMPK research progress |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1216907/full |
| work_keys_str_mv | AT ziyuanwang researchprogressofdihydromyricetininthetreatmentofdiabetesmellitus AT zhuorancao researchprogressofdihydromyricetininthetreatmentofdiabetesmellitus AT zhiyingyue researchprogressofdihydromyricetininthetreatmentofdiabetesmellitus AT zhengfengyang researchprogressofdihydromyricetininthetreatmentofdiabetesmellitus |